Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense oligonucleotides: towards clinical trials

S Agrawal1

  • 1Hybridon, Worcester, MA 10605, USA.

Trends in Biotechnology
|October 1, 1996
PubMed
Summary

Antisense oligonucleotides selectively block disease genes to inhibit protein production. First-generation drugs are in human trials, informing the development of improved second-generation antisense oligonucleotides.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.

British journal of cancer·2025
Same author

Dynamic versus fixed cerebral perfusion pressure targets in paediatric traumatic brain injury: a STARSHIP analysis.

EClinicalMedicine·2025
Same author

Stereoelectroencephalography (SEEG)-guided insula resections: is it "Reily" worth it?

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery·2024
Same author

What constitutes meaningful benefit of cancer drugs in the context of LMICs? A mixed-methods study of oncologists' perceptions on endpoints, benefit, price, and value of cancer drugs.

ESMO open·2024
Same author

Adopting prospective antimicrobial stewardship (AMS) practice in high-risk immunosuppressed groups: an urgent call to action in the era of antimicrobial resistance (AMR).

JAC-antimicrobial resistance·2024
Same author

Ultra-low oxygen, liquid sample cell for in situ synchrotron-based small-wide angle scattering (SAXS-WAXS).

The Review of scientific instruments·2023

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Genetics

Background:

  • Antisense oligonucleotides (ASOs) offer targeted gene silencing to inhibit disease-associated protein production.
  • ASO specificity and efficacy are validated in various animal models for diverse disease targets.
  • First-generation ASOs, specifically phosphorothioates, have advanced to human clinical trials.

Purpose of the Study:

  • To review the progress and potential of antisense oligonucleotide technology.
  • To highlight the transition from preclinical validation to clinical application of ASOs.
  • To establish a foundation for the design of next-generation ASOs based on current clinical data.

Main Methods:

  • Review of preclinical data demonstrating ASO specificity and application.
  • Analysis of pharmacological, pharmacodynamic, and pharmacokinetic profiles of first-generation ASOs.
  • Evaluation of ongoing human clinical trial data for safety and efficacy.

Main Results:

  • ASOs demonstrate significant potential in selectively targeting disease-causing genes.
  • Phosphorothioate ASOs have shown promise in preclinical studies and are currently undergoing human clinical trials.
  • Clinical trial data is crucial for understanding ASO safety and efficacy in humans.

Conclusions:

  • Antisense oligonucleotide technology is a validated therapeutic strategy with demonstrated potential.
  • Clinical trials with first-generation ASOs are essential for refining their application and safety.
  • Experience from current trials will guide the development of more advanced second-generation antisense oligonucleotides.

Related Experiment Videos